Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Saudi Arabia

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

- PMLiVE

Sanofi reveals positive phase 3 results for long-acting insulin Toujeo

Hopes new product can offset continuing decline in franchise

Article: Market access in Brazil

All eyes on Spinraza

Research Partnership

german flag

German pharma experiencing a ‘Brexit boost’

Opinion poll ranked Germany as top pharma market in EU

It’s the guns, stupid

Gun violence in the US – a public health issue – can be better understood through three points

- PMLiVE

Envision Pharma Group relocates to support expansion

Office moves in the US prompted by significant growth

- PMLiVE

AZ claims first-in-class win for Farxiga in heart failure

AZ in pursuit of class leader Jardiance

- PMLiVE

Amgen gets block on sales of Repatha rival in Germany

Part of ongoing battle with Sanofi and Regeneron

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Treatment can help patients with advanced disease, companies say

MIT reveals new pill to deliver insulin

A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...

Blue Latitude Health

Novartis day

Novartis close to US bribery settlement

Company faces huge damages pay out

A new vision for tackling key illnesses

Steve How and Oli Hudson, of Wilmington Healthcare, explore the NHS Long-term Plan’s strategy for delivering more preventative, joined-up services for major health conditions

Wilmington Healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links